Mirum Pharmaceuticals' LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older

Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and OlderDec 13, 2022- First and only medication approved in both the U.S. and Europe to treat cholestatic pruritus in patients with Alagille...

Related Keywords

United States ,France ,Germany ,Saclay ,France General ,Taiwan ,Paris ,United Kingdom ,Israel ,China ,South Korea ,Israeli ,Great Britain ,Chris Peetz ,Emmanuel Jacquemin ,Ale Kremlin ,Roberta Smith ,Instagram ,Mirum Pharmaceuticals ,Linkedin ,Twitter ,European Commission ,Drug Administration ,Alagille Syndrome Alliance ,Nasdaq ,Saclay University ,European Union ,Facebook ,Mirum Pharmaceuticals Inc ,Israeli Ministry Of Health ,Mirum Pharmaceutical ,Cholestatic Pruritus ,Alagille Syndrome Two Months ,European Committee ,Medicinal Products ,Human Use ,Israeli Ministry ,Professor Emmanuel Jacquemin ,Pediatric Hepatology ,Liver Transplantation Unit ,Paris Saclay University ,Alagille Syndrome ,Breakthrough Therapy ,Fat Soluble Vitamin ,